secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2026-07-30T20:08:09+00:00
Accession:  0001576280-26-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q2 revenue up 44% to $335M; raises 2026 guidance to $1.34-1.36B
-------------------------------------------------------------------------------

- Q2 revenue $335.0M (+44% YoY); Oncology $219.1M (+38%), Screening $52.9M (+258%).
- Net loss $120.1M ($0.90/share); non-GAAP net loss $56.2M ($0.42/share).
- 2026 revenue guidance raised to $1.34-1.36B (prior $1.30-1.32B), growth 36-38%.
- Screening revenue guidance raised to $218-230M; Shield volume 270k-285k tests.
- FDA approved Guardant360 Liquid CDx; Shield included in ACS guidelines, UnitedHealth coverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628026000036/0001576280-26-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628026000036/gh-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001576280-26-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer